日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

RRAS and RRAS2 Mutations Are Recurrent Oncogenic Drivers in Lung Cancer and Are Sensitive to the Pan-RAS Inhibitor RMC-6236

RRAS 和 RRAS2 突变是肺癌中常见的致癌驱动因素,并且对泛 RAS 抑制剂 RMC-6236 敏感。

Pfeil, Alexander J; Zhang, Tom; Cheng, Ryan; Mattar, Marissa S; Gomez Marti, Juan Luis; Gili, Leo; Lai, Rachel; Khodos, Inna; Master, Rohan P; Dix, Jenna-Marie; Gazzo, Andrea; Arbour, Kathryn C; de Stanchina, Elisa; Febres-Aldana, Christopher A; Ladanyi, Marc; Yang, Soo-Ryum; Somwar, Romel

Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy.

对致癌MET融合基因的泛癌分析揭示了对MET靶向治疗具有不同敏感性的不同致病基因组亚群

Febres-Aldana Christopher A, Vojnic Morana, Odintsov Igor, Zhang Tom, Cheng Ryan, Beach Catherine Z, Lu Daniel, Mattar Marissa S, Gazzo Andrea M, Gili Leo, Harshan Manju, Ameri Ali, Machnicki Stephen, Xiao Xiuying, Lockwood William W, Zhou Xiao-Yan, Yao Qianlan, Drilon Alexander, Rekhtman Natasha, Shah Nameeta, Li Anqi, Liu Zebing, Yang Soo-Ryum, Davare Monika A, Ladanyi Marc, Somwar Romel

Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas.

针对SMARCB1缺陷型肉瘤中PGBD5依赖性DNA损伤的表观遗传靶向治疗。

Kazansky Yaniv, Mueller Helen S, Cameron Daniel, Demarest Phillip, Zaffaroni Nadia, Arrighetti Noemi, Zuco Valentina, Mundi Prabhjot S, Kuwahara Yasumichi, Somwar Romel, Qu Rui, Califano Andrea, de Stanchina Elisa, Dela Cruz Filemon S, Kung Andrew L, Gounder Mrinal M, Kentsis Alex

Clinical and preclinical insights into a novel MDM2::PDGFRA fusion in recurrent glioblastoma

复发性胶质母细胞瘤中新型MDM2::PDGFRA融合的临床和临床前研究进展

Beach, Catherine Z; Febres-Aldana, Christopher A; Marti, Juan Luis Gomez; Asiry, Saeed; Wong, Tamika; Boockvar, John A; D'Amico, Randy S; Somwar, Romel; Davare, Monika A; Vojnic, Morana

Drug tolerance and persistence to EGFR inhibitor treatment are mediated by an ILK-SFK-YAP signaling axis in lung adenocarcinoma

肺腺癌中,药物耐受性和对EGFR抑制剂治疗的持续性是由ILK-SFK-YAP信号通路介导的。

Shi, Rocky; Farnsworth, Dylan A; Febres-Aldana, Christopher A; Chow, Justine L M; Sheena, Ravinder; Atwal, Tejveer; Gomez Marti, Juan Luis; Li, Samantha; Thomas, Kiersten N; Lee, Che-Min; Awrey, Shannon J; McDonald, Paul C; Somwar, Romel; Dedhar, Shoukat; Ladanyi, Marc; Bennewith, Kevin L; Lockwood, William W

ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results

CHK1/2激酶抑制剂ACR-368治疗复发或难治性促纤维增生性小圆细胞肿瘤患者的I/II期临床试验结果

Slotkin, Emily K; Mauguen, Audrey; Dela Cruz, Filemon S; Ortiz, Michael V; Avutu, Viswatej; Meyers, Paul A; Wexler, Leonard H; O'Donohue, Tara J; Kinnaman, Michael D; Kelly, Ciara M; D'Angelo, Sandra P; Keohan, Mary Lou; Gounder, Mrinal M; Thornton, Katherine; Nacev, Benjamin A; Chi, Ping; Rosenbaum, Evan; Dickson, Mark; Pachhal, Sagarika; Somwar, Romel; Ladanyi, Marc; Robb, Caroline; Pandit-Taskar, Neeta; Hwang, Sinchun; Price, Anita; Behr, Gerald; Reed, Damon R; Kentsis, Alex; Kung, Andrew L; Bender, Julia Glade; Tap, William D

RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236

RRAS 和 RRAS2 突变是肺癌中常见的致癌驱动因素,并且对泛 RAS 抑制剂 RMC-6236 敏感。

Pfeil, Alexander J; Zhang, Tom; Cheng, Ryan; Mattar, Marissa S; Gomez Marti, Juan Luis; Gili, Leo; Lai, Rachel; Khodos, Inna; Master, Rohan P; Dix, Jenna-Marie; Gazzo, Andrea; Arbour, Kathryn C; de Stanchina, Elisa; Febres-Aldana, Christopher A; Ladanyi, Marc; Yang, Soo-Ryum; Somwar, Romel

HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies

HER4 和 EGFR 激活 NRG1 融合驱动癌症中的细胞信号传导:对 HER2-HER3 特异性靶向与泛 HER 靶向策略的启示

Udagawa, Hibiki; Nilsson, Monique B; Robichaux, Jacqulyne P; He, Junqin; Poteete, Alissa; Jiang, Hong; Heeke, Simon; Elamin, Yasir Y; Shibata, Yuji; Matsumoto, Shingo; Yoh, Kiyotaka; Okazaki, Shogo; Masuko, Takashi; Odintsov, Igor; Somwar, Romel; Ladanyi, Marc; Goto, Koichi; Heymach, John V

Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.

非小细胞肺癌中高水平ERBB2扩增的流行情况及治疗靶点

Odintsov Igor, Makarem Maisam, Nishino Mizuki, Bachert Sara Emily, Zhang Tom, LoPiccolo Jaclyn, Paweletz Cloud P, Gokhale Prafulla C, Ivanova Elena, Saldanha Aisha, Rudin Charles M, Lockwood William W, Ladanyi Marc, Somwar Romel, Jänne Pasi A, Sholl Lynette M

Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets

BRAF融合基因的肿瘤非特异性基因组和临床分析可识别可操作的靶点

Chen, Monica F; Yang, Soo-Ryum; Tao, Jessica J; Desilets, Antoine; Diamond, Eli L; Wilhelm, Clare; Rosen, Ezra; Gong, Yixiao; Mullaney, Kerry; Torrisi, Jean; Young, Robert J; Somwar, Romel; Yu, Helena A; Kris, Mark G; Riely, Gregory J; Arcila, Maria E; Ladanyi, Marc; Donoghue, Mark T A; Rosen, Neal; Yaeger, Rona; Drilon, Alexander; Murciano-Goroff, Yonina R; Offin, Michael